Suzuki Takahiro, Yokoyama Yasuhisa, Kumano Keiki, Takanashi Minoko, Kozuma Shiro, Takato Tsuyoshi, Nakahata Tatsutoshi, Nishikawa Mitsuo, Sakano Seiji, Kurokawa Mineo, Ogawa Seishi, Chiba Shigeru
Department of Regeneration Medicine for Hematopoiesis, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Stem Cells. 2006 Nov;24(11):2456-65. doi: 10.1634/stemcells.2006-0258. Epub 2006 Jul 20.
Ex vivo expansion of hematopoietic stem cells (HSCs) has been explored in the fields of stem cell biology, gene therapy, and clinical transplantation. Here, we demonstrate efficient ex vivo expansion of HSCs measured by long-term severe combined immunodeficient (SCID) repopulating cells (SRCs) from human cord blood CD133-sorted cells using a soluble form of Delta1. After a 3-week culture on immobilized Delta1 supplemented with stem cell factor, thrombopoietin, Flt-3 ligand, interleukin (IL)-3, and IL-6/soluble IL-6 receptor chimeric protein (FP6) in a serum- and stromal cell-free condition, we achieved approximately sixfold expansion of SRCs when evaluated by limiting dilution/transplantation assays. The maintenance of full multipotency and self-renewal capacity during culture was confirmed by transplantation to nonobese diabetic/SCID/gammac(null) mice, which showed myeloid, B, T, and natural killer cells as well as CD133(+)CD34(+) cells, and hematopoietic reconstitution in the secondary recipients. Interestingly, the CD133-sorted cells contained approximately 4.5 times more SRCs than the CD34-sorted cells. The present study provides a promising method to expand HSCs and encourages future trials on clinical transplantation.
造血干细胞(HSCs)的体外扩增已在干细胞生物学、基因治疗和临床移植等领域得到探索。在此,我们展示了使用可溶性形式的Delta1从人脐带血CD133分选细胞中通过长期重度联合免疫缺陷(SCID)重建细胞(SRCs)来高效体外扩增HSCs。在无血清和无基质细胞条件下,将细胞接种于固定化Delta1上,并添加干细胞因子、血小板生成素、Flt-3配体、白细胞介素(IL)-3和IL-6/可溶性IL-6受体嵌合蛋白(FP6)进行3周培养后,通过有限稀释/移植试验评估,我们实现了SRCs约6倍的扩增。通过移植到非肥胖糖尿病/SCID/γc(null)小鼠中证实了培养过程中完全多能性和自我更新能力的维持情况,这些小鼠显示出髓系、B细胞、T细胞和自然杀伤细胞以及CD133(+)CD34(+)细胞,并且在二次受体中实现了造血重建。有趣的是,CD133分选细胞中的SRCs含量比CD34分选细胞多约4.5倍。本研究提供了一种有前景的扩增HSCs的方法,并鼓励未来进行临床移植试验。